We are live on ! Find out more
MIM

MetLife Investment Management Portfolio holdings

AUM $22.1B
1-Year Est. Return 45.54%
This Fund
S&P 500
This Quarter Est. Return
+4.29%
1 Year Est. Return
+45.54%
3 Year Est. Return
+139.2%
5 Year Est. Return
+180.26%
10 Year Est. Return
AUM
$20.7B
AUM Growth
-$166M
Cap. Flow
-$582M
Cap. Flow %
-2.82%
Top 10 Hldgs %
30.44%
Holding
2,896
New
52
Increased
415
Reduced
1,909
Closed
89

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$65.1M
2
AAPL icon
Apple
AAPL
+$58M
3
MSFT icon
Microsoft
MSFT
+$49.2M
4
EFA icon
iShares MSCI EAFE ETF
EFA
+$25.9M
5
AL
Air Lease Corp
AL
+$21.6M

Sector Composition

Rank Sector Weight
1 Technology 30.28%
2 Financials 13.29%
3 Healthcare 10.43%
4 Consumer Discretionary 10.39%
5 Industrials 9.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ONON icon
1651
On Holding
ONON
$10.6B
$670K ﹤0.01%
14,411
+308
+2% +$13.3K
PCT icon
1652
PureCycle Technologies
PCT
$1.41B
$665K ﹤0.01%
77,442
PRG icon
1653
PROG Holdings
PRG
$1.64B
$664K ﹤0.01%
22,514
-204
-0.9% -$6.08K
UCTT
1654
Ultra Clean Holdings
UCTT
$4.21B
$664K ﹤0.01%
26,200
OUST icon
1655
Ouster
OUST
$3.25B
$663K ﹤0.01%
30,622
BAM icon
1656
Brookfield Asset Management
BAM
$87.1B
$661K ﹤0.01%
12,620
-3
-0% -$161
XPRO icon
1657
Expro Ltd
XPRO
$2.07B
$660K ﹤0.01%
49,424
-7,070
-13% -$95.3K
PD icon
1658
PagerDuty
PD
$876M
$658K ﹤0.01%
50,169
-1,178
-2% -$17.2K
PCRX icon
1659
Pacira BioSciences
PCRX
$924M
$658K ﹤0.01%
25,411
-2,136
-8% -$50.8K
TDOC icon
1660
Teladoc Health
TDOC
$1.26B
$657K ﹤0.01%
93,800
-1,862
-2% -$14.6K
RLAY icon
1661
Relay Therapeutics
RLAY
$4.37B
$656K ﹤0.01%
77,536
+14,321
+23% +$102K
LFST icon
1662
Lifestance Health
LFST
$4.67B
$654K ﹤0.01%
92,939
+13,000
+16% +$78.4K
TRS icon
1663
TriMas Corp
TRS
$1.41B
$654K ﹤0.01%
18,440
-437,004
-96% -$15.3M
UNIT
1664
Uniti Group
UNIT
$2.31B
$649K ﹤0.01%
92,575
+9,377
+11% +$59.4K
JBGS
1665
JBG SMITH
JBGS
$691M
$648K ﹤0.01%
38,110
-81
-0.2% -$1.53K
ORKA
1666
Oruka Therapeutics
ORKA
$7.11B
$647K ﹤0.01%
21,362
+4,849
+29% +$135K
FWONK icon
1667
Liberty Media Series C
FWONK
$26B
$647K ﹤0.01%
6,571
-7
-0.1% -$687
CDRE icon
1668
Cadre Holdings
CDRE
$1.44B
$646K ﹤0.01%
15,806
-1,115
-7% -$46.4K
SRCE icon
1669
1st Source
SRCE
$2.13B
$645K ﹤0.01%
10,316
-712
-6% -$44K
PLGO
1670
Pelagos Insurance Capital
PLGO
$2.08B
$641K ﹤0.01%
32,777
-3,363
-9% -$62.7K
CMPR icon
1671
Cimpress
CMPR
$2.4B
$640K ﹤0.01%
9,615
+861
+10% +$58.4K
NVTS icon
1672
Navitas Semiconductor
NVTS
$3.57B
$638K ﹤0.01%
89,370
+15,713
+21% +$151K
PWP icon
1673
Perella Weinberg Partners
PWP
$1.28B
$637K ﹤0.01%
36,814
CAPR icon
1674
Capricor Therapeutics
CAPR
$244M
$634K ﹤0.01%
21,976
+7,740
+54% +$101K
SAFT icon
1675
Safety Insurance
SAFT
$1.52B
$630K ﹤0.01%
8,091
-596
-7% -$44.1K

Similar funds

MetLife Investment Management's Q4 2025 Portfolio in Review

As of Q4 2025, MetLife Investment Management held 2,896 positions worth $20.7B, down 0.8% from $20.8B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Trading was light in Q4 2025: portfolio turnover was 4.9%. MetLife Investment Management opened 52 new positions and exited 89, leaving the 2,896-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 31% a quarter earlier, followed by Financials and Healthcare.

  • MetLife Investment Management's largest Q4 2025 buy was RTX Corp: 321,368 shares worth $58.9M.
  • MetLife Investment Management added most to State Street SPDR S&P 500 ETF Trust in Q4 2025, an estimated $54.6M increase.
  • MetLife Investment Management's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $65.1M.
  • MetLife Investment Management fully exited Kellanova in Q4 2025, selling an estimated $5.48M.
  • MetLife Investment Management's ten largest holdings make up 30% of its $20.7B portfolio in Q4 2025.
  • MetLife Investment Management opened 52 new positions and closed 89 in Q4 2025.
  • MetLife Investment Management's portfolio value fell 0.8% quarter-over-quarter to $20.7B.

Based on MetLife Investment Management's 13F filing for Q4 2025, filed 12 Feb 2026.